/GDTC
GDTC Stock - CytoMed Therapeutics Limited
Healthcare|BiotechnologyNASDAQ
$1.41-9.62%
$0.15 (-9.62%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.55
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GDTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.40 – $1.42
TARGET (TP)$1.62
STOP LOSS$1.30
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.28
52W High$4.05
52W Low$1.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $52,005 | $290,560 | N/A | $84,178 | $44,923 |
| Gross Profit | $52,380 | $381,922 | $-81,034 | $81,587 | $41,427 |
| Gross Margin | 100.7% | 131.4% | N/A | 96.9% | 92.2% |
| Operating Income | $-2,626,170 | $-3,198,938 | $-1,696,781 | $-1,398,525 | $-1,003,131 |
| Net Income | $-1,883,178 | $-3,131,788 | $-2,270,655 | $-1,533,987 | $-1,467,218 |
| Net Margin | -3621.1% | -1077.8% | N/A | -1822.3% | -3266.1% |
| EPS | $-0.16 | $-0.29 | $-0.30 | $-0.22 | $-0.25 |
Company Overview
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GDTCBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.07
Q3 2025
EPS Surprise History
Q3 23
No data
Q1 24
No data
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 30, 2025 | — | $-0.07 | — | — |
Q2 2025 | Apr 28, 2025 | — | $-0.07 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.05 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.04 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-0.05 | — | — |
Q2 2024 | May 6, 2024 | — | $-0.05 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-0.03 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.05 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.10 | — | — |
Q2 2023 | May 1, 2023 | — | $-0.10 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.06 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.06 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.07 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.04 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.08 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.04 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.04 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.07 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.06 | — | — |
Latest News
CytoMed Therapeutics Enters MoU With Universiti Malaya Medical Centre To Establish Phase 1 Clinical Trial Site To Investigate Safety And Efficacy Of CTM-GDT for No-Option Cancer Patients
📈 PositiveBenzinga•Dec 8, 2025, 01:11 PM
CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia
📈 PositiveBenzinga•Dec 8, 2025, 01:08 PM
CytoMed Therapeutics' LongevityBank Secures A Non-Dilutive Investment From ICH Capital Of Up To $500K
📈 PositiveBenzinga•Nov 6, 2025, 01:30 PM
CytoMed Therapeutics' chairman increases effective holdings to 21.95%
📈 PositiveSeeking Alpha•Oct 22, 2025, 12:46 PM
CytoMed Therapeutics Chairman Increases Effective Holdings To 21.95% Through Open Market Purchases Of 105,824 Shares
📈 PositiveBenzinga•Oct 22, 2025, 12:07 PM
CytoMed Therapeutics Submits Cash Bid To Acquire TC BioPharm; Terms Not Disclosed
📈 PositiveBenzinga•Oct 14, 2025, 12:04 PM•Also:
CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
📈 PositiveBenzinga•Aug 28, 2025, 01:07 PM
Reported Earlier, CytoMed Therapeutics Limited Announces At The Market Offering Program For Up To $4.3M In Ordinary Shares Through R.F. Lafferty & Co Inc
➖ NeutralBenzinga•Aug 19, 2025, 06:32 AM•Also:
Frequently Asked Questions about GDTC
What is GDTC's current stock price?
CytoMed Therapeutics Limited (GDTC) is currently trading at $1.41 per share. The stock has moved -9.62% today.
What is the analyst price target for GDTC?
No analyst price targets are currently available for this stock.
What sector is CytoMed Therapeutics Limited in?
CytoMed Therapeutics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GDTC's market cap?
CytoMed Therapeutics Limited has a market capitalization of $0.02 billion, making it a small-cap company.
Does GDTC pay dividends?
No, CytoMed Therapeutics Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
LSTA
Lisata Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NCNA
NuCana plc
$3.56
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
PASG
Passage Bio, Inc.
$9.59
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to GDTC for comparison